Literature DB >> 8164217

Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study.

H Mielants1, E M Veys, C Cuvelier, M De Vos, S Goemaere, M Maertens, R Joos.   

Abstract

Ileocolonoscopy with biopsy of the colon and terminal ileum was performed prospectively on 12 patients under age 16 with late onset juvenile chronic arthritis (JCA). Inflammatory gut lesions were seen in 9 of these 12 patients; 4 were of the acute type, 5 of the chronic type. Chronic gut inflammation was related to axial inflammatory complaints, inflammatory serum variables, thrombocytosis and sacroiliac radiological abnormalities. A 2nd ileocolonoscopy was performed on 5 of the 12 patients, and a 3rd ileocolonoscopy on 2 of these with persistent synovitis. Gut inflammation and joint inflammation were related; moreover, all 5 patients had chronic inflammatory lesions by the time of the last investigation, one presented with Crohn's disease. The 12 patients were reviewed 3 to 9 years after the first ileocolonoscopy. Four patients were in remission, including the 3 patients with initial normal gut histology. Five patients had developed ankylosing spondylitis (AS), a 6th patient possible AS. Axial inflammatory complaints, a family history of spondyloarthropathies, HLA-B27 positivity, early sacroiliac and peripheral joints radiographic changes, persistence of inflammatory serum variables, thrombocytosis and chronic inflammatory lesions on gut biopsy, are predictive factors in juveniles for evolution to AS. Late onset pauciarticular JCA represents a form of spondyloarthropathy similar to adolescent forms. Persistent gut inflammation could play a role in the pathogenesis of the disease and persistent synovitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8164217

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  29 in total

Review 1.  The transition of acute to chronic bowel inflammation in spondyloarthritis.

Authors:  Liesbet Van Praet; Peggy Jacques; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2012-04-17       Impact factor: 20.543

2.  Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.

Authors:  Matthew L Stoll; Marilynn Punaro; Ashish S Patel
Journal:  J Rheumatol       Date:  2011-10       Impact factor: 4.666

Review 3.  Juvenile spondyloarthritis.

Authors:  Sabrina Gmuca; Pamela F Weiss
Journal:  Curr Opin Rheumatol       Date:  2015-07       Impact factor: 5.006

Review 4.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

Review 5.  Current issues in pediatric inflammatory bowel disease-associated arthropathies.

Authors:  Sabrina Cardile; Claudio Romano
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

6.  Mucosal inflammation in spondylarthritides: past, present, and future.

Authors:  Liesbet Van Praet; Filip Van den Bosch; Herman Mielants; Dirk Elewaut
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

7.  Faecal microbiome in new-onset juvenile idiopathic arthritis.

Authors:  M V Tejesvi; M Arvonen; S M Kangas; P L Keskitalo; A M Pirttilä; T J Karttunen; P Vähäsalo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-30       Impact factor: 3.267

Review 8.  Gut inflammation and microbiome in spondyloarthritis.

Authors:  Jayakanthan Kabeerdoss; Pulukool Sandhya; Debashish Danda
Journal:  Rheumatol Int       Date:  2015-12-30       Impact factor: 2.631

Review 9.  Juvenile onset spondyloarthropathies: therapeutic aspects.

Authors:  R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

10.  Protective effect of naringin against ankylosing spondylitis via ossification, inflammation and oxidative stress in mice.

Authors:  Kang Liu; Lianguo Wu; Xiaolin Shi; Fengqing Wu
Journal:  Exp Ther Med       Date:  2016-05-31       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.